Page 19 - P4403.14_V92_YOUROTC_Book MAY_2024 NI
P. 19
HEALTHCARE 19
Introducing a NEW pharmacy-exclusive pain reliever PAIN MANAGEMENT 5 DEPTH
†
IN
MINUTES CPD CPD
Learning:
+ How SolpaOne® is different from
other paracetamol options
+ Benefits of SolpaOne® and when
MINUTE
to recommend CPD
+ The role of SolpaOne® in the context
of everyday pain management
ALL THE PAIN RELIEF
YOUR CUSTOMERS
NEED IN ONE TABLET
Maximum strength
pharmacy-only paracetamol
in a single effervescent tablet *
Save † New brand
Personal Pharmacy Training * 1 tablet = 1 dose (take only one tablet at a time)
9% Off
Trade
Help your customers' pain dissolve away
Perrigo, the makers of Solpadeine – No. 1 Pharmacy brand in adult oral analgesics – bring you an effervescent one-dose
1
®
Help your customers' pain dissolve away CONVENIENCE & COMPLIANCE
paracetamol tablet suitable for all types of mild-moderate pain and also for people with swallowing difficulties.
2,3
KEY BENEFITS
GETS TO WORK UP TO 2X FASTER
2x
SolpaOne® is rapidly absorbed and
SolpaOne® offers the convenience of two 500mg
works up to 2x faster than regular
paracetamol tablets in a single max dose offering.
Easy-to-swallow, and contains a max-strength 1000 mg
paracetamol tablets *
of paracetamol to aid with dosage compliance
GENTLE ON THE STOMACH
SODIUM CONSCIOUS SolpaOne® is gentle on the stomach 4
Perrigo, the makers of Solpadeine – No. 1 Pharmacy brand in adult oral analgesics – bring you an effervescent one-dose
SolpaOne® is a sodium-conscious product
®
1
SolpaOne® delivers the trusted and familiar pain relief of paracetamol in an innovative effervescent format.
Now you can recommend a new pharmacy-only paracetamol, that is both effective and convenient to take.
†
paracetamol tablet suitable for all types of mild-moderate pain and also for people with swallowing difficulties. 2,3
*Based on absorption data † New brand
1. IRI Value Sales, date accessed 52w/e October 2023. 2. SolpaOne® Summary of Product Characteristics. July 2021. 3. Wright D, et al. Consensus guideline on the medication management of adults with swallowing difficulties.
Medendium Group Publishing Ltd 2006. Available at: https://docplayer.net/55029179-Consensus-guideline-on-the-medication-management-of-adults-with-swallowing-difficulties.html 4. NHS: Paracetamol for adults.
Available at: https://www.nhs.uk/medicines/paracetamol-for-adults/ Accessed November 2023.
PRODUCT INFORMATION
SolpaOne 1000 mg Effervescent Tablets (P) contain paracetamol. For short term symptomatic treatment of mild to moderate pain and/or fever. Adults and children over 16 years and weighing over 50 kg: 1 tablet dissolved in water every
6 hours as needed. Max 4 tablets in 24 hours. Do not use in children under 16 years and weighing less than 50 kg.Do not take with other paracetamol-containing products. In case of overdose, seek immediate medical advice, even if the patient
feels well. Contraindications: known hypersensitivity to the ingredients. Caution: renal or hepatic impairment, chronic alcoholism, non-cirrhotic alcoholic liver disease, Gilbert’s syndrome, haemolytic anaemia, dehydration or chronic
malnutrition, glucose-6-phosphate dehydrogenase deficiency, paracetamol can interfere with laboratory tests. Product contains sodium (1 tablet equivalent to 26.68% recommended daily intake) and sorbitol. Interactions: probenecid,
cholestyramine, rifampicin, carbamazepine, phenytoin, phenobarbital, primidone, warfarin and other coumarins, salicylamide, metoclopramide, domperidone, isoniazid, flucloxacillin, St John’s wort, and chloramphenicol. Side effects:
hypersensitivity reaction, angioedema, anaphylactic shock, aspirin-sensitive bronchospasm, platelet disorders, stem cell disorders, thrombocytopenia, leukopenia, haemolytic anaemia, pancytopenia, methaemoglobinaemia, agranulocytosis,
hepatic failure, hepatic necrosis, hepatitis, severe renal impairment, gastrointestinal haemorrhage, hypoglycaemia, Interstitial nephritis and serious skin reactions. PL 36390/0411. MAH: Cipla (EU) Limited Dixcart House, Addlestone Road,
Bourne Business Park, Addlestone, Surrey, KT15 2LE, UK. Date of preparation: 06/2023. RRP (ex. VAT): 12s £5.19. SPC: https://mhraproducts4853.blob.core.windows.net/docs/f433587536fc4ebbcbb10e2c53c96c280676733d
Personal Pharmacy Training UK/2023-258
KEY BENEFITS
2x GETS TO WORK UP TO 2X FASTER CONVENIENCE & COMPLIANCE
SolpaOne® is rapidly absorbed and SolpaOne® offers the convenience of two 500mg
works up to 2x faster than regular paracetamol tablets in a single max dose offering.
paracetamol tablets * Easy-to-swallow, and contains a max-strength 1000 mg
of paracetamol to aid with dosage compliance
SODIUM CONSCIOUS GENTLE ON THE STOMACH
SolpaOne® is a sodium-conscious product SolpaOne® is gentle on the stomach 4
SolpaOne® delivers the trusted and familiar pain relief of paracetamol in an innovative effervescent format.
Now you can recommend a new pharmacy-only paracetamol, that is both effective and convenient to take.
†
* Based on absorption data New brand
†
1. IRI Value Sales, date accessed 52w/e October 2023. 2. SolpaOne® Summary of Product Characteristics. July 2021. 3. Wright D, et al. Consensus guideline on the medication management of adults with swallowing difficulties.
Medendium Group Publishing Ltd 2006. Available at: https://docplayer.net/55029179-Consensus-guideline-on-the-medication-management-of-adults-with-swallowing-difficulties.html 4. NHS: Paracetamol for adults.
Available at: https://www.nhs.uk/medicines/paracetamol-for-adults/ Accessed November 2023.
PRODUCT INFORMATION
SolpaOne 1000 mg Effervescent Tablets (P) contain paracetamol. For short term symptomatic treatment of mild to moderate pain and/or fever. Adults and children over 16 years and weighing over 50 kg: 1 tablet dissolved in water every
6 hours as needed. Max 4 tablets in 24 hours. Do not use in children under 16 years and weighing less than 50 kg.Do not take with other paracetamol-containing products. In case of overdose, seek immediate medical advice, even if the patient
feels well. Contraindications: known hypersensitivity to the ingredients. Caution: renal or hepatic impairment, chronic alcoholism, non-cirrhotic alcoholic liver disease, Gilbert’s syndrome, haemolytic anaemia, dehydration or chronic
malnutrition, glucose-6-phosphate dehydrogenase deficiency, paracetamol can interfere with laboratory tests. Product contains sodium (1 tablet equivalent to 26.68% recommended daily intake) and sorbitol. Interactions: probenecid,
cholestyramine, rifampicin, carbamazepine, phenytoin, phenobarbital, primidone, warfarin and other coumarins, salicylamide, metoclopramide, domperidone, isoniazid, flucloxacillin, St John’s wort, and chloramphenicol. Side effects:
hypersensitivity reaction, angioedema, anaphylactic shock, aspirin-sensitive bronchospasm, platelet disorders, stem cell disorders, thrombocytopenia, leukopenia, haemolytic anaemia, pancytopenia, methaemoglobinaemia, agranulocytosis,
hepatic failure, hepatic necrosis, hepatitis, severe renal impairment, gastrointestinal haemorrhage, hypoglycaemia, Interstitial nephritis and serious skin reactions. PL 36390/0411. MAH: Cipla (EU) Limited Dixcart House, Addlestone Road,
Bourne Business Park, Addlestone, Surrey, KT15 2LE, UK. Date of preparation: 06/2023. RRP (ex. VAT): 12s £5.19. SPC: https://mhraproducts4853.blob.core.windows.net/docs/f433587536fc4ebbcbb10e2c53c96c280676733d
Personal Pharmacy Training
UK/2023-258
